Penumbra, Inc. (PEN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 560 | 748 | 847 | 1,059 | 1,195 | 1,404 | 1,505 | 1,590 |
| Operating profit | $m | 189 | 187 | ||||||
| Net profit | $m | -16 | 5 | -2 | 91 | 14 | 178 | 161 | 192 |
| EPS reported | $ | 4.52 | 4.07 | ||||||
| Operating cashflow per share | $ | 6.13 | 7.07 | ||||||
| Capex per share | $ | 1.64 | 1.57 | ||||||
| FCF per share | $ | 4.49 | 5.49 | ||||||
| Free cash flow | $m | 175 | 216 | ||||||
| Net debt | $m | -545 | -659 | ||||||
| Book value equity | $m | 1,428 | 1,531 | ||||||
| Book value per share | $ | 36.33 | 38.68 | ||||||
| Number of shares | m | 39.29 | 39.57 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 68.79 | 78.35 | ||||||
| P/B LTM | x | 8.48 | 7.90 | ||||||
| P/S LTM | x | 8.62 | 8.04 | ||||||
| P/FCF LTM | x | 69.17 | 56.04 | ||||||
| EV/EBITDA LTM | x | 54.19 | 54.59 | ||||||
| EV/Sales LTM | x | 8.64 | 8.56 | ||||||
| Earnings Yield LTM | % | +1.45% | +1.28% | ||||||
| FCF Yield | % | +1.45% | +1.78% | ||||||
| Quality | |||||||||
| ROE | % | +12.45% | +11.09% | ||||||
| ROIC | % | +9.88% | +8.40% | ||||||
| Operating margin | % | +13.48% | +12.45% | ||||||
| Gross margin | % | +67.14% | +67.84% | ||||||
| FCF/Sales | % | +12.46% | +14.35% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +1155.6% | +1030.6% | ||||||
| Sales Growth YoY | % | +17.50% | +25.97% | ||||||
| Net Income Growth YoY | % | +1168.1% | +1046.1% | ||||||
| FCF Growth | % | +18.76% | +46.58% | ||||||
| Operating Profit Growth | % | +119.49% | +117.28% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.80 | 1.02 | ||||||
| Net Debt/EBITDA | x | 0.15 | 0.03 | ||||||
| EBIT/Net interest | x | 144.35 | 144.22 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.38 | -0.43 | ||||||
| Gross debt/equity | x | 0.15 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free